Physician profile
Mark F Peake
NPI 1336244581
$2,886.45
in general payments reported to CMS, 2019-2025
18 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $146 · 2021: $274 · 2022: $531 · 2023: $643 · 2024: $563 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.01 | 2019-2024 | |
| Incyte Corporation | $327.41 | 2022-2025 | Opzelura |
| Amgen INC. | $285.36 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $216.40 | 2020-2024 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $205.11 | 2019-2023 | Simponi, Stelara, Remicade |
| E.R. Squibb & Sons, L.L.C. | $175.32 | 2022-2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $144.91 | 2019-2023 | Dupixent |
| Lilly USA, LLC | $142.37 | 2022-2024 | Taltz, Olumiant |
| Dusa Pharmaceuticals, INC. | $131.94 | 2019 | |
| Pfizer INC. | $96.86 | 2019-2024 | |
| Journey Medical Corporation | $59.75 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.77 | 2022 | |
| Celgene Corporation | $53.35 | 2019 | |
| Ucb, INC. | $46.17 | 2023 | Bimzelx |
| Genzyme Corporation | $26.61 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $20.60 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.61 | 2024 | Zoryve |
| Organon LLC | $4.90 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Peake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.